A prospective split-face pilot study of an ambient-light photobiomodulation silicone patch: overnight (9-h) effects on facial skin viscoelasticity (DTM310) and imaging-based condition (DermaVision)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0012151

Enrollment

Registered

2026-06-22

Start date

2026-01-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Medical Device : Overall Overview - Light Patch: Red luminescent particles in a silicone matrix emit continuous low-intensity light under indoor white light, enabling 9-hour non-powered PBM during sle

side randomized. - Visit Schedule: Day -1 evening: consent/screening, baseline DermaVision/Dermal Torque Meter(DTM)310, and 24-h forearm patch test. Night -1 to Day 2: patch applied to treatment cheek

illuminance recorded. Procedures and Interventions - Marking/Skin Preparation: Non-permanent marks on both malar regions

light alcohol swab

5-min stabilization. - Dermal Torque Meter(DTM) 310, Non-invasive: Three repeats at the same site

5 mm main and 1 mm auxiliary ring spacing. Outputs: maximum rotation angle, recovery angle, recovery ratio. - DermaVision, Non-invasive: Fixed posture, distance, exposure, and gain. Frontal and left/r

same region of interest on both cheeks. - Patch Application, Treatment Side Only: Standardized attachment with hypoallergenic tape and/or silicone patch, avoiding wrinkles and hair overlap. Kept for 9

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adults aged 19–65 years, female or male, who are in good general health; Fitzpatrick skin types I–IV; no active facial skin disease; no cosmetic procedures, such as laser treatment, fillers, or botulinum toxin injection, within the past 1 month; and willing to maintain their usual skincare routine during the study period.

Exclusion criteria

Exclusion criteria: Individuals with photosensitive diseases or taking photosensitizing medications; history of allergy to adhesives or silicone; pregnancy or breastfeeding; severe acne or dermatitis; any condition requiring dermatological treatment; or individuals judged by the investigator to be unsuitable for participation.

Design outcomes

Primary

Measure	Time frame
DTM310 viscoelasticity indices (primary); DermaVision imaging indices (secondary)	—

Secondary

Measure	Time frame
Assessment of skin abnormalities and completion of the adverse event (AE) checklist	—

Countries

Korea, Republic of

Contacts

Public ContactSeong-Jong Kim

Pohang University of Science and Technology

sjkim1382@postech.ac.kr+82-54-279-2159

Outcome results